Osivax Reports Phase 2b Results for OVX836

and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines.

Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines

Phase 2b study provides first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes
OVX836 did not meet its pre-specified primary endpoint of 50% vaccine efficacy
Results support development of OVX836 in combination with traditional seasonal influenza vaccines to provide a complementary layer of protection
Strategic collaborations with GC Biopharma and a second, undisclosed global pharmaceutical partner enable next phase of combination vaccine development